Jean-Michel Coindre is an expert in Oncology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Jean-Michel Coindre in the top 1% of experts worldwide for Sarcoma. Jean-Michel Coindre has authored 627 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 1,912 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-Michel Coindre Institut Bergonié France
1 912 ScienceLeadR Reputation 1912
Network Map

Oncology

Subspecialties: Histology - Genetics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1988 - 2026

Source: PubMed

INSERM

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 627

Citations

Citations: 36 257 1st author: 35 Last author: 114 Unique author: 40


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO).
PMID 42735453 — rhabdomyosarcoma, neoplasms, drug therapy, sarcoma, aged, adolescent, therapeutics, prognosis, chemotherapy
ESMO Open20260
Feasibility and activity of concurrent neoadjuvant chemotherapy and radiation therapy in patients with high-risk soft tissue sarcoma.
PMID 42531374 — radiotherapy, epirubicin, ifosfamide, neoplasms, drug therapy, sarcoma, therapeutics, tissues, chemotherapy
Clin Cancer Res20260
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.
PMID 42291149 — registries, cohort studies, drug therapy, sarcoma, chemotherapy, adjuvant, work, therapeutics, tissues, aids-related complex, chemotherapy
EClinicalMedicine20263
Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue Sarcomas.
PMID 42279277 — margins of excision, neoplasms, tertiary lymphoid structures, biomarkers, sarcoma, tissues, tumor microenvironment
Cancers (Basel)20261
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.
PMID 42258704 — gastrointestinal stromal tumors, neoplasms, exons, deep learning, protein-tyrosine kinases, tyrosine, therapeutics, learning, mutation, landslides
Cancer Res20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 2
Phase 1/Phase 2 2
Phase 3 2
Phase 2 1

By status:

Completed 4
Recruiting 2
Active not recruiting 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 2
multicentricup10 5

Main Topics

LeadR Networks

Main global connection map